摘要
目的明确血管内皮生长因子受体(VEGFR)及血小板衍生因子受体(PDGFR)在肾癌组织中表达情况,了解舒尼替尼的适用个体。方法建立裸鼠背部皮下人肾癌移植瘤模型,根据VEGFR-3、PDGFRα是否表达,分为VEGFR阳性组、PDGFR阳性组、双阳组、双阴组,各组内设给药组与对照组。分别于药后第5、20天及自然死亡后穿刺取活检测定瘤组织中VEGFR-3、PDGFRα表达强度的变化,记录生存时间。结果各给药组之间生存时间的差别有统计学意义(F=32.58,P<0.001),VEGFR-3、PDGFRα表达强度呈下降趋势。结论舒尼替尼可延长VEGFR-3、PDGFRα阳性表达荷瘤裸鼠的总生存期,对肾癌个性化治疗有一定的指导意义。
Objective To explicit the expression of vascular endothelial growth factor receptor （VEGFR） and platelet derivative factor receptor （PDGFR） in the kidney cancer, and to understand Sunitinib for individual and resistance of the production process. Methods Models of human renal cell carcinoma transplanted subcutaneously were established, according to the expressed VEGFR and PDGFR, which was divided into VEGFR positive group, PDGFR positive group, VEGFR and PDGFR both positive group, the double negative group, and the team was further divided into treatment group and control group. The expression and change level of VEGFR-3 and PDGFR α were observed after the treatment in 5th days, 20th days and natural death piercing taking biopsy in determination tumor tissue, respectively, the survival time was recorded. Results The differents between the survival times of the four positive group had statistic meanings （=32.58,〈 0.001）. The trend of the expressing level of VEGFR-3 and PDGFRα was drawing. Conclusion Sunitinib can prolong the oerall surial of tumor-burdened nude mouse which expressses VEGFR-3 and PDGFRα, and it has certain directive significance in personalized treatment for kidney cancer.
出处
《中国医药导报》
CAS
2012年第19期31-32,共2页
China Medical Herald
基金
中国临床肿瘤学科学基金资助项目(项目编号:Y-H2010-012)
关键词
舒尼替尼
裸鼠
肾癌
个性化治疗
Sunitinib
Node mouse
Kidney cancer
Personalized treatment
